Skip navigation
Skip navigation
You are using an outdated browser. Please upgrade your browser.

Marking a major step forward in the use of Terahertz for commercial drug development

28 February 2005: Cambridge, England: TeraView Ltd, the company that launched the world’s first commercial Terahertz spectrometer, today announced the availability of the world’s first Terahertz spectrometer capable of making measurements in multiple sampling geometries, the Spectra 1000D. Building on the success of the Spectra 1000, the latest addition to Teraview’s Terahertz spectroscopy portfolio combines reflective spectroscopy with its existing transmission spectroscopy technology.

The Spectra 1000D has already been ordered by leading pharmaceutical companies, and offers chemists and material scientists new flexibility in the presentation and analysis of polymorphic, crystalline and amorphous substances in the research and development cycle.

By offering both ATR and specular reflection sampling geometries in modular form, in addition to the existing transmission sampling, the user can choose the best measurement method for an extensive range of sample types, including liquids, powders, gels, creams, films and reflective surfaces. With the new ATR module, the user can also select between Germanium and Silicon crystals, allowing spectroscopic information to be gathered from different depths from the sample surface.

TeraView’s existing transmission spectroscopy capabilities have set the market parameters for the use of Terahertz in the analysis of intermolecular relationships in the research and development cycle and have provided a new understanding of polymorphic behaviour.

“With the introduction of Terahertz reflectance spectroscopy, Teraview is continuing to deliver tools that offer immediate business benefits to the pharmaceutical industry,” said John Paul Cerroti, VP Sales & Product Development at TeraView. “The Spectra 1000D enables faster and earlier insights into the polymorphic behaviour of drug candidates, which enables significant acceleration of the development process, giving attractive cost savings and speeding the production of high quality, stable drugs and medication.”

About TeraView
TeraView is a UK company established in April 2001 to develop and exploit terahertz technology and develop innovative products to meet customer needs. TeraView has engineered the technology into practical systems for use in pharmaceutical and medical markets, producing the world’s first commercial terahertz imagers and spectrometers.

TeraView is also at the forefront of developing terahertz technology for security applications and in June 2004 announced a strategic partnership with leading vendor, Smiths Detection. With 34 staff based in Cambridge, England, TeraView is the only company solely focused on terahertz technology and is widely recognised as having a world-leading position in terahertz imaging and spectroscopy.

For more product information please contact:
John Paul Cerroti
TeraView Limited
+44 (0) 122 343 5380
john.paul.cerroti@teraview.com
www.teraview.com

For press enquiries please contact:
Caroline Howlett
Nelson Bostock Communications
+44 (0) 20 7792 7444
caroline.howlett@nelsonbostock.com
www.nelsonbostock.com




This press release was distributed by ResponseSource Press Release Wire on behalf of Nelson Bostock Unlimited in the following categories: Consumer Technology, Business & Finance, Computing & Telecoms, for more information visit https://pressreleasewire.responsesource.com/about.